Advertisement
12/27/2022

Yaral Pharma launches in the U.S.

Yaral Pharma will begin commercializing the first product from IBSA’s corporate pipeline of authorized generics in January 2023.
Sandra Levy
Senior Editor
Sandra Levy profile picture

Yaral Pharma, the U.S. generics subsidiary of IBSA, a long-standing, multinational pharmaceutical company headquartered in Lugano, Switzerland, launched today with the mission of providing access to high quality, affordable, authorized generics and complex generic medicines.

Led by a team of industry veterans, Yaral Pharma will begin commercializing the first product from IBSA’s corporate pipeline of authorized generics in January 2023. Yaral Pharma’s current portfolio includes products across a range of therapeutic areas, including pain and endocrinology. It plans to rapidly expand its product line and therapeutic areas of focus through outside opportunities and external partnerships.

[Read more: Challenges continue, but generics companies see a bright future with biosimilars]

IBSA is particularly known for its manufacturing expertise and decades-long track record of product quality and supply continuity. The company noted that it continues to build a wide-ranging portfolio of products across brands and generics in 10 core therapeutic areas, including pain, inflammation and endocrinology, and manufactures novel delivery systems such as soft gel capsules and patch technology. IBSA also is recognized as one of the largest players worldwide in the area of reproductive medicine and hyaluronic acid-based products, the company said.

“Our parent company IBSA is recognized as a world leader in the development of innovative technologies and products that improve the health and wellness of people,” said Stephen Beckman, CEO of Yaral Pharma. “We look forward to drawing on these strengths and providing our customers with high-quality products, continuity of supply, and exceptional levels of service.”

    Advertisement
    Advertisement